For citations:
Wirth L.J., Durante C., Topliss D.J., Winquist E., Robenshtok E., Iwasaki H., Luster M., Elisei R., Leboulleux S., Tahara M. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer: treatment optimization for maximum clinical benefit. Head and Neck Tumors (HNT). 2022;12(4):81-90. (In Russ.) https://doi.org/10.17650/2222-1468-2022-12-4-81-90
Email this article 